alpha-MSH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
== History == In December 2008, the US Food and Drug Administration (FDA) approved degarelix for the treatment of people with advanced prostate cancer. It was subsequently approved by the European Commission at the recommendation of the European Medicines Agency (EMA) in February 2009, for use in adult males with advanced, hormone-dependent prostate cancer. Ferring Pharmaceuticals markets the drug under the name Firmagon.
=== Cell junctions === Cell junctions are especially abundant in epithelial tissues. They regulate interactions between neighbouring cells or between a cell and the extracellular matrix or contribute to the paracellular barrier of epithelia and regulate paracellular transport. There are 5 main types of cell junctions, each composed of different protein complexes:
== Imaging techniques == The high sensitivity of DESI in the lipid range makes it a powerful technique for the detection and mapping of lipids abundances within tissue specimens. Recent developments in MALDI methods have enabled direct detection of lipids in-situ. Abundant lipid-related ions are produced from the direct analysis of thin tissue slices when sequential spectra are acquired across a tissue surface that has been coated with a MALDI matrix. Collisional activation of the molecular ions can be used to determine the lipid family and often structurally define the molecular species. These techniques enable detection of phospholipids, sphingolipids and glycerolipids in tissues such as heart, kidney and brain. Furthermore, distribution of many different lipid molecular species often define anatomical regions within these tissues.
Sources: en.wikipedia.org
Widespread use Spironolactone — the first and most widely used member of this class Eplerenone — much more selective than spironolactone on target, but somewhat less potent and efficacious Uncommon use (to date) Canrenone and potassium canrenoate — very limited use Finerenone — nonsteroidal and more potent and selective than either eplerenone or spironolactone Some drugs also have antimineralocorticoid effects secondary to their main mechanism of actions. Examples include progesterone, drospirenone, gestodene, metribolone, and benidipine.
A gunshot wound (GSW) is a penetrating injury caused by a projectile (e.g., a bullet) shot from a gun. Damage may include bleeding, bone fractures, organ damage, wound infection, and loss of the ability to move part of the body. Damage depends on the part of the body hit, the path the bullet follows through (or into) the body, and the type and speed of the bullet, and can be fatal. Long-term complications can include bowel obstruction, failure to thrive, neurogenic bladder and paralysis, recurrent cardiorespiratory distress and pneumothorax, hypoxic brain injury leading to early dementia, amputations, chronic pain and pain with light touch (hyperalgesia), deep venous thrombosis with pulmonary embolus, limb swelling and debility, and lead poisoning. Factors that determine rates of gun violence vary by country. These factors may include the illegal drug trade, easy access to firearms, substance misuse including alcohol, mental health problems, firearm laws, social attitudes, economic differences, and occupations such as being a police officer. Where guns are more common, altercations more often end in death; however, firearm laws, particularly background checks and permit to purchase, can decrease this risk. Safer firearm storage may decrease the risk of firearm-related deaths in children. Before management begins, the area must be verified as safe. This is followed by stopping major bleeding, then assessing and supporting the airway, breathing, and circulation. In 2015, about a million gunshot wounds occurred from interpersonal violence.
Aflatoxin B1 and B2 (AFB), produced by A. flavus and A. parasiticus Aflatoxin G1 and G2 (AFG), produced by some Group II A. flavus and Aspergillus parasiticus Aflatoxin M1 (AFM1), metabolite of aflatoxin B1 in humans and animals (exposure in ng levels may come from a mother's milk) Aflatoxin M2, metabolite of aflatoxin B2 in milk of cattle fed on contaminated foods Aflatoxicol (AFL): metabolite produced by breaking down the lactone ring Aflatoxin Q1 (AFQ1), major metabolite of AFB1 in in vitro liver preparations of other higher vertebrates AFM, AFQ, and AFL retain the possibility of becoming an epoxide. Nevertheless, they appear much less capable of causing mutagenesis than the unmetabolized ABM.
Sources: en.wikipedia.org
=== Opposition front bencher: 1967–70 === In 1967, Peter Walker invited Heseltine to be opposition spokesman on transport (not a Shadow Cabinet-level position, but reporting to Walker), after he had arranged a successful speaking tour of the West Country for him. Heseltine's duties included opposing Barbara Castle's 1967 Transport Bill (which eventually became the Transport Act 1968). Heseltine led opposition to the parts of the bill which nationalised small bus companies into the National Bus Company (UK) and set up Passenger transport executives (PTEs) in major urban areas. He criticised Castle for wanting to give PTEs the right to manufacture or produce anything necessary for their function, which as she pointed out was almost word-for-word identical to a clause in the Conservatives' Transport Act 1962. In 1968 Margaret Thatcher became Heseltine's boss for a year; he found her "embarrassingly rude". Unusually for the time, he employed a full-time researcher, Eileen Strathnaver. Heath allowed his shadow ministers more leeway than would be normal nowadays. Heseltine was one of a group of 15 Conservative MPs to vote against the 1968 Commonwealth Immigration Bill on second reading (Conservative whips advised their MPs to support it, but it was a free vote). He also voted against the bill on three subsequent votes, arguing that it was based on "sheer naked racialism" and that Britain should honour promises previously made to the Kenyan Asians.
=== Bi–Bo === Klaus Biemann (1926–2016). Austrian chemist at MIT, the "father of organic mass spectrometry" and particularly noted for his role in advancing protein sequencing with tandem mass spectrometry. Member Natl. Acad. Sci. USA. Ethel Ronzoni Bishop (1890–1975). American biochemist and physiologist at Washington University in St. Louis who studied carbohydrate metabolism. Pamela J. Bjorkman (b. 1956). American biochemist at Caltech, who studies immune recognition of viral pathogens. Member Natl. Acad. Sci. USA. Elizabeth Blackburn AC FRS FAA FRSN (b. 1948). Australian-American biochemist, Nobel Laureate, co-discoverer of telomerase. Konrad Emil Bloch FRS (1912–2000). German-American biochemist at Harvard, who worked on the mechanism and regulation of cholesterol and fatty acid metabolism. Nobel Prize in Physiology or Medicine 1964. Elkan Blout (1919–2006). American biochemist at Harvard, who worked on peptide structure and conformation, including cyclic peptides. Member Natl. Acad. Sci. USA. David Mervyn Blow FRS (1931–2004). British X-ray crystallographer at Imperial College London, who worked on protein structure. Tom Blundell, FRS (b. 1942). British biochemist at the University of Cambridge, structural biologist, and science administrator. Aaron Bodansky (1887–1960). Russian-born American biochemist at the Hospital for Joint Diseases, New York, specializing in the area of calcium metabolism. Paul D. Boyer (1918–2018). American biochemist, at UCLA who studied ATP synthase. Nobel Prize in Chemistry in 1997. Member Natl. Acad. Sci. USA.
Ampicillin/sulbactam is also used when the cause of an infection is not known (empiric therapy), such as intra-abdominal infections, skin infections, pneumonia, and gynecologic infections. It is active against a wide range of bacterial groups, including Staphylococcus aureus, Enterobacteriaceae, and anaerobic bacteria. Importantly, it is not active against Pseudomonas aeruginosa and should not be used alone when infection with this organism is suspected or known.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.